GILD
70.96
-0.65 (-0.91%)
Gilead Sciences, Inc (NASDAQ, USD)
Healthcare >
Drug Manufacturers-General
Market cap
89.00B
Ent value
133.46B
Price/Sales
3.60
Price/Book
4.69
Div yield
4.00%
Div growth
-
Growth years
6
FCF payout
45.88%
Trailing P/E
723.55
Forward P/E
10.67
PEG
516.82
EPS growth
-10.50%
1 year return
9.09%
3 year return
-1.24%
5 year return
-2.07%
10 year return
13.68%
Last updated: 2021-09-20
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 70.93 |
| Daily high | 71.91 |
| Daily low | 70.34 |
| Daily Volume | 9.33M |
| All-time high | 122.21 |
| 1y analyst estimate | 74.49 |
| Beta | 0.40 |
| EPS (TTM) | 0.10 |
| Dividend per share | 2.84 |
| Ex-div date | 14 Sep 2021 |
| Next earnings date | 27 Oct 2021 |
Downside potential
Loading...
Downside potential data
| GILD | S&P500 | |
| Current price drop from All-time high | -41.94% | -4.23% |
| Highest price drop | -70.83% | -56.47% |
| Date of highest drop | 7 Jun 1994 | 9 Mar 2009 |
| Avg drop from high | -24.18% | -11.47% |
| Avg time to new high | 23 days | 12 days |
| Max time to new high | 1573 days | 1805 days |
DIVIDENDS
Dividend yield - 5y
Loading...
Dividend yield data
| Dividend per share | 2.84 |
| Dividend yield | 4.00% |
| Payout frequency | Quarterly |
| Maximum yield | 5.01% |
| Average yield | 3.53% |
| Minimum yield | 2.30% |
| Discount to avg yield | 11.82% |
| Upside potential | 13.40% |
| Yield as % of max yield | 79.84% |
Yield distribution (inverse percentile) - 5y
Loading...
Yield distribution data
| Dividend yield | 4.00% |
| Current yield distribution | 24.92% |
| Yield at 100% (Min) | 2.30% |
| Yield at 90% | 2.77% |
| Yield at 80% | 2.92% |
| Yield at 50% (Median) | 3.62% |
| Yield at 20% | 4.12% |
| Yield at 10% | 4.32% |
| Yield at 0% (Max) | 5.01% |
Dividend per share
Loading...
Dividend per share data
| Years of growth | 6 years |
| CCC status | Dividend Challenger |
| Dividend per share | 2.84 |
| Payout frequency | Quarterly |
| Ex-div date | 14 Sep 2021 |
| EPS (TTM) | 0.10 |
| EPS (1y forward) | 6.65 |
| EPS growth (5y) | -10.50% |
| EPS growth (5y forward) | 1.40% |
Dividend growth
Loading...
Please create a free account or log in to access this chart
Dividend growth data
| GILD | S&P500 | |
| DGR MR | 4.41% | 7.68% |
| DGR TTM | 5.24% | -2.66% |
| DGR 3 years | 9.35% | 5.82% |
| DGR 5 years | - | 6.23% |
| DGR 10 years | - | 9.64% |
| DGR 15 years | - | 6.71% |
| Time since last change announced | 232 days |
| EPS growth (5y) | -10.50% |
| EPS growth (5y forward) | 1.40% |
Payout ratio
Loading...
Please create a free account or log in to access this chart
Payout ratio data
| EPS coverage | FCF coverage | |
| TTM | 2804.07% | 45.88% |
| Average | - | - |
| Forward | 42.71% | - |
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | 723.55 |
| Price to OCF | 10.90 |
| Price to FCF | 11.84 |
| Price to EBITDA | 28.26 |
| EV to EBITDA | 42.38 |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 3.60 |
| Price to Book | 4.69 |
| EV to Sales | 5.41 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 1.25B |
| EPS (TTM) | 0.10 |
| FCF per share (TTM) | 6.00 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 24.69B |
| Gross profit (TTM) | 20.12B |
| Operating income (TTM) | 4.13B |
| Net income (TTM) | 123.00M |
| EPS (TTM) | 0.10 |
| EPS (1y forward) | 6.65 |
Margins
Loading...
Margins data
| Gross margin (TTM) | 81.48% |
| Operating margin (TTM) | 16.75% |
| Profit margin (TTM) | 0.50% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 4.07B |
| Net receivables | 3.92B |
| Total current assets | 13.28B |
| Goodwill | 8.33B |
| Intangible assets | 34.78B |
| Property, plant and equipment | 4.99B |
| Total assets | 67.49B |
| Accounts payable | 4.08B |
| Short/Current long term debt | 30.17B |
| Total current liabilities | 9.71B |
| Total liabilities | 48.53B |
| Shareholder's equity | 18.96B |
| Net tangible assets | -24.16B |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | 8.17B |
| Capital expenditures (TTM) | 650.00M |
| Free cash flow (TTM) | 7.52B |
| Dividends paid (TTM) | 3.45B |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | 0.68% |
| Return on Assets | 0.18% |
| Return on Invested Capital | 0.25% |
| Cash Return on Invested Capital | 15.15% |
COMPANY DETAILS
Marketcap
89.00B
Marketcap category
Large-cap
Description
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Employees
13600
Website
Investor relations
SEC filings
CEO
Daniel O'Day
Country
USA
City
Foster City
Stock type
Common stock
CCC status
Dividend Challenger
Dividend Frequency
Quarterly
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
All newsPress releases
September 21, 2021
Myelodysplastic syndromes, or MDS, is a rare type of blood cancer primarily affecting people over the age of 65. In fact, it’s such a rare and largely unknown illness that most people living with M...
September 20, 2021
Gilead Sciences (GILD) closed at $70.96 in the latest trading session, marking a -0.91% move from the prior day.
September 20, 2021
Suzanne Judd, Ph.D., Epidemiologist at the University of Alabama at Birmingham School of Public Health, joins Yahoo Finance to discuss the latest on the coronavirus pandemic.
September 20, 2021
FOSTER CITY, Calif., September 20, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the upcoming presentation of new data from the company’s virology research and development programs at the...
September 17, 2021
Yahoo Finance’s Anjalee Khemlani reports the FDA advisory panels' second vote regarding Covid-19 boosters.
September 17, 2021
Yahoo Finance’s Anjalee Khemlani reports the latest on the FDA’s decision regarding covid booster shots.
September 17, 2021
Dr. Hiral Tipirneni, Emergency Medicine Physician, joins Yahoo Finance Live to discuss the latest on the coronavirus pandemic.
September 17, 2021
Dr. Elizabeth Clayborne, Adjunct Assistant Professor of Emergency Medicine at the University of Maryland School of Medicine and Emergency Physician at UM Capital Region Medical Center, joins Yahoo Fin...
September 16, 2021
Gilead Sciences Inc (NASDAQ: GILD) announced new data from the Phase 3 ASCENT study of Trodelvy (sacituzumab govitecan-hziy) in relapsed or refractory metastatic triple-negative breast cancer (TNBC) w...
September 16, 2021
FOSTER CITY, Calif., September 16, 2021--Gilead Sciences, Inc. (Nasdaq: GILD) today announced new data from the Phase 3 ASCENT study of Trodelvy® (sacituzumab govitecan-hziy) in patients with relapsed...
Next page